MKI67 and cancer: Our cohort demonstrated that the AYA group exhibited more aggressive cancer subtypes compared to the OA group, with 23.8% being triple negative, 61.3% showing high Ki-67 levels, and a higher proportion having stage 3+ disease, thus confirming the aforementioned points.